Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease

Osteoprotegerin (OPG), the neutralizing decoy receptor for the osteoclast activator RANK ligand, was measured in serum taken from patients with multiple myeloma at the time of diagnosis. Median OPG was lower in the patients with myeloma (7.4 ng/mL; range, 2.6-80; n = 225) than in healthy age- and se...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2001-10, Vol.98 (7), p.2269-2271
Main Authors: Seidel, Carina, Hjertner, Øyvind, Abildgaard, Niels, Heickendorff, Lene, Hjorth, Martin, Westin, Jan, Nielsen, Johan Lanng, Hjorth-Hansen, Henrik, Waage, Anders, Sundan, Anders, Børset, Magne
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Case-Control Studies
Glycoproteins - blood
Health Status Indicators
Humans
Immunodeficiencies. Immunoglobulinopathies
Immunoglobulinopathies
Immunopathology
Medical sciences
Middle Aged
Multiple Myeloma - blood
Multiple Myeloma - complications
Osteolysis - blood
Osteolysis - etiology
Osteoprotegerin
Receptors, Cytoplasmic and Nuclear - blood
Receptors, Tumor Necrosis Factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Osteoprotegerin (OPG), the neutralizing decoy receptor for the osteoclast activator RANK ligand, was measured in serum taken from patients with multiple myeloma at the time of diagnosis. Median OPG was lower in the patients with myeloma (7.4 ng/mL; range, 2.6-80; n = 225) than in healthy age- and sex-matched controls (9.0 ng/mL; range 5.1-130; n = 40; P = .02). Importantly, OPG levels were associated with degree of radiographically assessed skeletal destruction (P = .01). The median OPG level in patients lacking osteolytic lesions was 9.1 ng/mL, as compared with 7.6 ng/mL and 7.0 ng/mL, respectively, in patients with minor or advanced osteolytic disease. Furthermore, OPG levels were associated with World Health Organization performance status (P = .003) and correlated to serum levels of carboxy-terminal propeptide of type I procollagen (PICP; P < .001) but not with clinical stage or survival. These findings suggest impaired OPG function in myeloma and give a rationale for OPG as a therapeutic agent against myeloma bone disease.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V98.7.2269